Assigned to MyMD Pharmaceuticals, Inc., Baltimore, MD (US)
Filed by MyMD Pharmaceuticals, Inc., Baltimore, MD (US)
Filed on Jun. 28, 2022, as Appl. No. 17/851,862.
Application 17/851,862 is a division of application No. 17/524,304, filed on Nov. 11, 2021.
Application 17/524,304 is a continuation of application No. 16/928,255, filed on Jul. 14, 2020, granted, now 11,219,620, issued on Jan. 11, 2022.
Application 16/928,255 is a continuation in part of application No. 16/680,677, filed on Nov. 12, 2019, granted, now 11,179,382, issued on Nov. 23, 2021.
Application 16/680,677 is a continuation of application No. 15/719,875, filed on Sep. 29, 2017, granted, now 10,517,856, issued on Dec. 31, 2019.
Application 15/719,875 is a continuation in part of application No. PCT/US2016/025126, filed on Mar. 31, 2016.
Claims priority of provisional application 62/140,618, filed on Mar. 31, 2015.
Prior Publication US 2022/0339147 A1, Oct. 27, 2022
1. A method of treating a disease of the visual system selected from the group consisting of uveitis, glaucoma, and age-related macular degeneration (AMD), the method comprising administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle thereof.